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Aims Orthostatic hypotension (OH) has been linked to increased mortality and incidence of cardiovascular disease in
various risk groups, but determinants and consequences of OH in the general population are poorly studied.
Methods
and results
Prospective data of the Swedish ‘Malmo ¨ Preventive Project’ (n ¼ 33 346, 67.3% men, mean age 45.7+7.4 years,
mean follow-up 22.7+6.0 years) were analysed. Orthostatic hypotension was found in 6.2% of study participants
and was associated with age, female gender, hypertension, antihypertensive treatment, increased heart rate, diabetes,
low BMI, and current smoking. In Cox regression analysis, individuals with OH had signiﬁcantly increased all-cause
mortality (in particular those aged less than 42 years) and coronary event (CE) risk. Mortality and CE risk were dis-
tinctly higher in those with systolic blood pressure (BP) fall  30 mmHg [hazard ratio (HR): 1.6, 95% CI 1.3–1.9,
P , 0.0001 and 1.6, 95% CI 1.2–2.1, P ¼ 0.001] and diastolic BP fall  15 mmHg (HR: 1.4, 95% CI 1.1–1.9,
P ¼ 0.024 and 1.7, 95% CI 1.1–2.5, P ¼ 0.01). In addition, impaired diastolic BP response had relatively greater
impact (per mmHg) on CE incidence than systolic reaction.
Conclusion Orthostatic hypotension can be detected in 6% of middle-aged individuals and is often associated with such comor-
bidities as hypertension or diabetes. Presence of OH increases mortality and CE risk, independently of traditional risk
factors. Although both impaired systolic and diastolic responses predict adverse events, the diastolic impairment
shows stronger association with coronary disease.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Orthostatic blood pressure (BP) control involves complex com-
pensatory mechanisms allowing the human body to stand
upright.
1 As the postural homeostasis is principally mediated by
autonomic nervous system, its impairment may lead to BP fall
after standing. The phenomenon, denominated as orthostatic
hypotension (OH), is often associated with debilitating symptoms:
fatigue, dizziness, and fainting.
2–4 Orthostatic hypotension has
been deﬁned by the international consensus as a decrease in
systolic BP   20 mmHg and/or decrease in diastolic BP  
10 mmHg within 3 min of standing.
5,6 In addition, some authors
have proposed standing systolic BP , 90 mmHg as an alternative
criterion.
7
Clinicians are usually interested in diagnosing OH as it can cause
fall-related injuries,
8 substantially limit patients’ quality of life,
9 and
ﬁnally, impede relevant treatment of concomitant diseases as
hypertension or heart failure.
10,11 In parallel, relatively little is
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incidence of cardiovascular disease (CVD) related to prevalent
OH has been reported in different high-risk groups
12–14 with dom-
inantly symptomatic patients. However, the number of studies
regarding the prognostic value of younger and mainly asympto-
matic individuals without signiﬁcant burden of co-morbidities is
limited. Prospective data from the Atherosclerosis Risk in Commu-
nities (ARIC) study suggest that OH may confer higher risk of all-
cause mortality and cardiovascular events.
15–17
Consequently, the aim of our study was to explore prevalence,
determinants, and major consequences [total mortality, coronary
event (CE), and stroke] of impaired postural haemodynamic
response in a Swedish urban middle-aged cohort of the Malmo ¨
Preventive Project (MPP).
Methods
Study population and baseline examination
The Malmo ¨ Preventive Project was started in the mid-1970s at the
Malmo ¨ University Hospital,
18 which is the main hospital in the
Malmo ¨ city area (population of 280 000). Between 1974 and 1992,
a total of 22 444 men and 10 902 women were recruited and screened
for hypertension, diabetes, hyperlipidaemia, smoking, family history,
previous diseases, and other all-cause mortality and CVD risk
factors. Specially trained nurses performed all examinations in the
morning. The invited men and women were fasting overnight prior
to investigation. Height and weight were measured in light indoor
clothing. A complete medication list was recorded for each participant.
Blood samples were collected and plasma lipids (total cholesterol and
triglycerides) were analysed by routine methods at the Department of
Clinical Chemistry, Malmo ¨ University Hospital. Fasting plasma glucose
was analysed with a hexokinase method. Afterwards, the participants
answered a questionnaire of 260 questions using a computer. The
questions centred on own and family history of CVD (myocardial
infarction and stroke), hypertension, diabetes and cancer, smoking
habits (those who conﬁrmed regular or occasional current smoking
were counted as smokers), physical activity at work and during
leisure time, dietary habits and weight gain, alcohol consumption,
presence of symptoms and signs indicating coronary heart disease,
cardiac failure, hypertension, or stroke. The following questions
were valid for the history of CVD, if the answer was yes: have you
ever been hospitalized for myocardial infarction/stroke? Men were
recruited mainly in the years 1974–1981 and woman in the years
1982–1992, which resulted in different mean age in these two
groups at the screening [men (mean age+SD; range, in years):
43.7+6.6; 26.5–61.2 and women: 49.7+7.4; 28.2–57.6]. A detailed
description of recruitment and screening procedures may be found
elsewhere.
18–20
Blood pressure measurements
Blood pressure (mmHg) was measured auscultatorily by specially
trained nurses in two different positions (supine and standing), with
a mercury sphygmomanometer and an appropriate cuff placed
around the right arm. First BP reading was taken after 10 min rest in
the supine position. Then the participants were asked to stand up
and the second BP measurement was taken after 1 min. Blood pressure
was determined and recorded to the nearest 5 mmHg. Complete data
on 32 797 participants were available (missing data n ¼ 549).
Deﬁnition of orthostatic hypotension
Orthostatic hypotension at the baseline was deﬁned according to the
international consensus as a decrease in systolic BP   20 mmHg and/
or decrease in diastolic BP  10 mmHg within 3 min of standing, or,
in addition, as standing systolic BP ,90 mmHg.
Deﬁnition of hypertension and diabetes
For the purposes of this study, hypertension at the screening was
deﬁned according to the present guidelines as systolic BP  
140 mmHg and/or diastolic BP  90 mmHg, or use of antihypertensive
treatment.
21
Diabetes was deﬁned as fasting plasma glucose  7.0 mmol/L or
current pharmacological treatment of diabetes or self-reported
history of diabetes.
Follow-up and endpoints
All participants were followed-up until the 31 December 2005 through
linkage of the 10-digit personal identiﬁcation number of each Swedish
citizen with three registries: the Swedish National Hospital Discharge
Register (SNHDR), the Swedish National Cause of Death Register
(SNCDR), and the Stroke Register of Malmo ¨ (STROMA). Participants
who emigrated from Sweden before 31 December 2005 and had been
event-free at the time of emigration (n ¼ 641) received the date of
emigration as the last follow-up date. The mean follow-up time was
22.7+6.0 years.
Coronary event was deﬁned as fatal or non-fatal myocardial infarc-
tion or death due to coronary heart disease on the basis of the Inter-
national Classiﬁcation of Diseases 9th and 10th Revisions (ICD9 and
ICD10) codes 410 and I21, respectively, in the SNHDR and codes
410, 412, and 414 (ICD9) or I21–I23 and I25 (ICD10) in the
SNCDR. The register-based diagnosis of CE in the SNHDR has been
found to be highly valid.
22
Fatal or non-fatal stroke was deﬁned according to ICD9 and ICD10
as cases coded 430, 431, 434, and 436 or I60, I61, I63, and I64, respect-
ively. STROMA, which continuously and actively has searched for and
validated patients with stroke since 1989 (including imaging tech-
niques),
23 was used for case retrieval. The research nurse, together
with a senior physician, validated the diagnosis through medical
records and in most cases also through a patient interview. The cri-
terion for stroke was rapid development of clinical signs of local or
global loss of cerebral function lasting for .24 h or leading to death
at ,24 h, with no apparent cause other than cerebral ischaemia or
haemorrhage. By deﬁnition, patients with transient ischaemic attacks
were excluded. The criterion for stroke classiﬁed as subarachnoid
haemorrhage or intracerebral haemorrhage was veriﬁcation of the
clinical picture by CT, lumbar puncture, or necropsy.
24 For those par-
ticipants who experienced stroke before 1989, available medical
records were validated using the same procedure as STROMA. In
addition, SNHDR and SNCDR were used for retrieval of patients
who moved out of Malmo ¨. In subjects with more than one CE or
stroke, only the ﬁrst event was used for the analysis.
Statistical analysis
Groupwise differences in continuous variables were compared using
t-test and variables that were not normally distributed were log-
transformed prior to analysis. Dichotomous variables were compared
using x
2 test. Presence of OH at the baseline was ﬁrst related to differ-
ent covariates in an unadjusted model. Thereafter, we performed a
logistic regression analysis, entering OH as the dependent variable
and age, gender, body mass index (BMI), total cholesterol, triglycerides,
heart rate, haemoglobin, creatinine, hypertension, antihypertensive
A. Fedorowski et al. 86treatment, diabetes, current smoking, history of CVD, and history of
cancer as independent variables, in order to identify determinants
of OH.
Presence of OH at the baseline was related to all-cause mortality,
ﬁrst-incident CE, and ﬁrst-incident stroke and, additionally, to ﬁrst
composite endpoint (ﬁrst-incident CV event, stroke or CE, or
death) during follow-up in crude and multivariate adjusted Cox pro-
portional hazard models. All participants with positive history of
CVD prior to the baseline examination (n ¼ 159) were excluded.
The multivariate adjusted analyses included the following covariates:
age, gender, current smoking, BMI, hypertension, diabetes, total
cholesterol (HDL and LDL cholesterol were not analysed in MPP),
and previous cancer (for mortality analysis only).
Analyses were repeated for three different age groups: less than 42
years (n ¼ 9395), 42–48 years (n ¼ 11 043), and  48 years (n ¼
12 357) as previous reports suggested that younger OH positive indi-
viduals might be at relatively higher mortality risk.
16
Furthermore, analyses were also repeated for conventional (systolic
BP fall  20 mmHg and diastolic BP fall  10 mmHg) and higher cut-off
limits (systolic BP fall  30 mmHg and diastolic BP fall  15 mmHg) as
BP values recorded at baseline examination were rounded to the
nearest 5 mmHg, which might have classiﬁed some borderline cases
as falsely OH positive. Systolic and diastolic covariates were analysed
separately.
In addition, associations between a continuous variable—orthostatic
BP reaction (OBPR, D mmHg¼supine BP2standing BP) and all three
endpoints were examined using the same Cox proportional hazard
models, separately for systolic and diastolic OBPR. In these analyses,
OBPR was adjusted for supine systolic BP and antihypertensive treat-
ment instead of the dichotomous variable of hypertension. Potential
interactions between supine systolic BP and OBPR were assessed.
All calculations were performed using SPSS statistical software
version 16.0 for Windows (SPSS Inc., 233 S. Wacker Drive, Chicago,
IL 60606-6307, USA). All tests were two-sided and a P , 0.05 was
considered statistically signiﬁcant.
Results
In total, 6.2% of study participants (n ¼ 2033) were found having
OH at the baseline. Orthostatic hypotension prevalence in men
was 5.3% (n ¼ 1186) and in women 8.1% (n ¼ 847).
One thousand three hundred and seventy-four individuals (4.1%)
were classiﬁed as OH positive according to systolic OBPR  
20 mmHg and 802 (2.4%) based on diastolic OBPR   10 mmHg.
Only 168 individuals (0.5%) fulﬁlled both criteria. Additionally,
25 participants (0.1%) had standing systolic BP, 90 mmHg.
As can be seen in Table 1, OH positive individuals were older,
more likely to be women and current smokers. Furthermore,
OH was correlated with statistically signiﬁcant higher prevalence
of hypertension, diabetes, previous CVD, and antihypertensive
treatment, as well as with higher heart rate, systolic and diastolic
BP, and triglycerides at the baseline screening. In the multivariate
analysis, the following independent OH determinants were ident-
iﬁed: age, per year [odds ratio (OR): 1.05, 95% conﬁdence interval
(CI) 1.04–1.06], female gender (OR: 1.29, 95% CI 1.16–1.43),
hypertension (OR: 2.35, 95% CI 2.10–2.62), antihypertensive
treatment (OR: 1.35, 95% CI 1.15–1.60), diabetes (OR: 1.38,
95% CI 1.13–1.67), BMI, per kg/m
2 (OR: 0.96, 95% CI 0.95–
0.97), current smoking (OR: 1.37, 95% CI 1.24–1.52, P , 0.001
for all), and heart rate, per beat/min (OR: 1.006, 95% CI 1.001–
1.011, P ¼ 0.013).
During the follow-up period 6904 individuals (20.7%) died, 3849
(11.5%) suffered from CE and 2134 (6.4%) were diagnosed with
incident stroke (86.4% ischaemic, 12.6% haemorrhagic, 1.0%
unspeciﬁed). Orthostatic hypotension positive individuals demon-
strated higher all-cause mortality risk, both in crude [hazard ratio
(HR): 1.66, 95% CI 1.53–1.81, P , 0.001] and in adjusted model
(HR: 1.19, 95% CI 1.09–1.30, P , 0.001), higher CE risk in
crude (HR: 1.58, 95% CI 1.41–1.77, P , 0.001) and adjusted
model (HR: 1.18, 95% CI 1.05–1.33, P ¼ 0.007), and higher risk
of composite endpoint in both models (HR: 1.59, 95% CI 1.47–
1.71, P , 0.001 and 1.18, 1.09–1.27, P , 0.001). Orthostatic hypo-
tension was also related to higher stroke risk in a crude model
(HR: 1.59, 95% CI 1.36–1.85, P , 0.001), but this association
was attenuated after adjustment for conventional CVD risk
factors (HR: 1.11, 95% CI 0.95–1.30, P ¼ 0.21). Effects of baseline
OH status on all-cause mortality, incidence of CE, stroke, and com-
posite endpoint in the MPP cohort are presented as multivariate
adjusted Cox regression plots in Figures 1–4.
While repeating analyses in the predeﬁned age groups (Table 2),
the following observations were made: mortality risk was more
than two times higher in OH positive individuals who were
younger than 42 years, and conversely, incidence of CE in the
same age group showed no signiﬁcant association with the baseline
OH. In parallel, impact of OH on all-cause mortality and CE in the
................................................................................
Table 1 Correlates of orthostatic hypotension in the
Malmo ¨ Preventive Project in an unadjusted model
presented as means with standard deviation or
percentages
Covariate OH negative
(n 5 30 764)
OH positive
(n 5 2033)
P-value
Age (years) 45.4+7.4 48.8+7.2 ,0.001
Gender (male,%) 68.9 58.3 ,0.001
BMI 24.57+3.6 24.62+4.0 0.505
Total cholesterol
(mmol/L)
5.7+1.1 5.8+1.2 ,0.001
Triglycerides
(mmol/L)
1.38+0.9 1.44+1.1 0.007
Heart rate (b.p.m.) 67.4+9.7 68.9+10.8 ,0.001
Systolic BP (mmHg) 125.7+14.9 136.3+20.2 ,0.001
Diastolic BP
(mmHg)
84.1+9.5 88.1+11.3 ,0.001
Haemoglobin (g/L) 144.3+12.0 143.0+12.6 ,0.001
Creatinine (mmol/L) 87.8+18.8 86.3+17.9 ,0.001
Hypertension (%) 38.9 61.4 ,0.001
Diabetes (%) 4.6 7.4 ,0.001
Current smoker (%) 45.1 48.7 0.002
History of CVD (%) 0.5 1.0 0.001
History of cancer
(%)
1.7 2.1 0.215
Antihypertensive
treatment (%)
5.0 12.1 ,0.001
OH predicts all-cause mortality and CEs 87two remaining age groups (42–48 years and over 48 years) was
substantially the same as for the whole cohort, whereas association
between baseline OH and composite endpoint was attenuated
with increasing age.
In the multivariate adjusted model, all-cause mortality, CE, and
composite endpoint risks were distinctly higher in those partici-
pants who fulﬁlled more restrictive OH criteria: systolic BP fall
 30 mmHg (n ¼ 220; HR: 1.59, 95% CI 1.29–1.97, P , 0.001;
1.60, 1.21–2.10, P ¼ 0.001; and 1.42, 1.18–1.72, P , 0.001,
respectively) or diastolic BP fall  15 mmHg (n ¼ 124; HR: 1.40,
95% CI 1.01–1.93, P ¼ 0.042; 1.65, 1.10–2.46, P ¼ 0.015; and
1.35, 1.02–1.77, P ¼ 0.035, respectively). In parallel, conventional
diagnostic limits were associated with relative risk corresponding
to that of pooled OH group (data not shown).
Figure 1 Orthostatic hypotension (OH) and all-cause mor-
tality. One Minus Survival Function adjusted for age, gender,
BMI, hypertension, diabetes, total cholesterol, smoking, and pre-
vious cancer.
Figure 2 Orthostatic hypotension (OH) and coronary events.
One Minus Coronary Event–Free Survival Function adjusted for
age, gender, BMI, hypertension, diabetes, total cholesterol, and
smoking.
Figure 3 Orthostatic hypotension (OH) and stroke. One
Minus Stroke Event–Free Survival Function adjusted for age,
gender, BMI, hypertension, diabetes, total cholesterol, and
smoking.
Figure 4 Orthostatic hypotension (OH) and composite end-
point (CE, stroke, and death). One Minus Event–Free Survival
Function adjusted for age, gender, BMI, hypertension, diabetes,
total cholesterol, and smoking.
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OBPR were 1.2+8.8 and 22.2+5.4 mmHg, respectively. As
shown in Table 3, both systolic and diastolic OBPR were related
to increased mortality, and higher CE and stroke incidence in the
crude models. After adjustment for conventional risk factors,
although both systolic and diastolic reactions predicted higher all-
cause mortality, increased CE risk remained signiﬁcantly associated
with diastolic BP fall only. Only one signiﬁcant (P ¼ 0.028) inter-
action was detected between supine systolic BP and systolic
OBPR in the analysis of total mortality. We decided therefore to
repeat this analysis in the following subgroups stratiﬁed by systolic
BP ,140 mmHg (normotensive),  140 and ,160 mmHg (mild
hypertension), and  160 mmHg (moderate-to-severe hyperten-
sion). The strongest association between systolic OBPR and
all-cause mortality was found in the middle stratum  140 and
,160 mmHg [HR (per 10 mmHg): 1.07, 95% CI 1.02–1.12, P ¼
0.011], then in the normotensive individuals (1.04, 1.00–1.08,
P ¼ 0.029), whereas association in the highest stratum
 160 mmHg was not signiﬁcant (1.03, 0.95–1.11, P ¼ 0.423).
Discussion
Orthostatic hypotension has been traditionally associated with
neurodegenerative diseases (e.g. Parkinson’s disease, multiple
system atrophy, or autonomic neuropathies),
25 frail elderly
patients
3,26,27 and chronic heart failure.
9,28,29 Furthermore, both
hypertension
30–32 and diabetes
33,34 have been related to impaired
orthostatic homeostasis through mechanisms, which are not yet
completely understood. In such high-risk settings, OH demon-
strates higher prevalence than in the general population, suggesting
a multifactorial aetiology of postural haemodynamic failure. So the
question arises when do OH-related disorders start in life and
what are the main predisposing factors for developing OH?
To our knowledge, this is the largest longitudinal study exploring
prevalence of OH in an unselected middle-aged urban population.
In the MPP cohort, 6% of all individuals, aged between 28 and
61 years, predominantly free from advanced chronic diseases at
baseline, met the criteria of OH. This prevalence is close to that
reported in the ARIC study, where 5.1% of participants were
...............................................................................................................................................................................
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Table 3 Relationships between orthostatic blood pressure reaction and all-cause mortality, coronaryevent, stroke, and
composite endpoint in crude and adjusted Cox regression models (hazard ratio, 95% conﬁdence interval, P-value)
Endpoint Systolic OBPR
a Diastolic OBPR
a
All-cause mortality 1.21 (1.18–1.23), P , 0.001 1.18 (1.13–1.22), P , 0.001
1.05 (1.02–1.07), P ¼ 0.001
b 1.05 (1.01–1.10), P ¼ 0.017
b
Coronary event 1.17 (1.13–1.21), P , 0.001 1.20 (1.14–1.26), P , 0.001
1.02 (0.99–1.06), P ¼ 0.213
b 1.09 (1.03–1.15), P ¼ 0.003
b
Stroke 1.17 (1.12–1.22), P , 0.001 1.19 (1.11–1.27), P , 0.001
0.98 (0.93–1.03), P ¼ 0.488
b 1.06 (0.99–1.14), P ¼ 0.111
b
Composite endpoint (CE, stroke, or death) 1.18 (1.15–1.20), P , 0.001 1.17 (1.13–1.21), P , 0.001
1.04 (1.02–1.06), P ¼ 0.001
b 1.05 (1.01–1.09), P ¼ 0.011
b
aOBPR effects are presented for 10 mmHg difference.
bCox proportional hazard model adjusted for age, gender, SBP, AHT, total cholesterol, diabetes, BMI, current smoking, previous CVD, and cancer (mortality only).
...............................................................................................................................................................................
Table 2 Orthostatic hypotension related risk of mortality, coronary event, and stroke by age-stratiﬁed subgroups of
MPP in multivariate
a adjusted Cox regression model (hazard ratio, 95% conﬁdence interval, and P-value)
Age groups <42 years  42 and <48 years  48 years
Total number of individuals 9396 11 044 12 357
Male (%) 83.3 88.6 37.3
OH positive (%) 3.1 5.7 9.0
Number of deaths/CEs/strokes 920/606/292 2545/1559/820 3 381/1662/1001
Events (death, CE, and stroke) per 1000 person-years 3.90/2.57/1.24 9.85/6.03/3.17 13.41/6.59/3.97
All-cause mortality risk 1.46 (1.07–2.00), P ¼ 0.017 1.21 (1.04–1.41), P ¼ 0.012 1.17 (1.04–1.31), P ¼ 0.007;
CE risk 1.06 (0.68–1.67), P ¼ 0.786 1.19 (0.98–1.45), P ¼ 0.077 1.20 (1.03–1.40), P ¼ 0.022
Stroke risk 0.92 (0.47–1.79), P ¼ 0.799 1.16 (0.88–1.52) P ¼ 0.300 1.13 (0.92–1.38) P ¼ 0.251
Composite endpoint (CE, stroke, or death) risk 1.27 (0.98–1.65) P ¼ 0.073 1.24 (1.09–1.41) P ¼ 0.001 1.14 (1.03–1.26) P ¼ 0.010
aCox proportional hazard model adjusted for age, gender, hypertension, total cholesterol, diabetes, BMI, current smoking, and cancer (mortality only).
OH predicts all-cause mortality and CEs 89found having OH.
16 Similar to the ARIC study, age, hypertension,
diabetes, current smoking, and history of CVD were related to
OH. However, we found that OH may be also determined by
female gender, antihypertensive treatment, and low BMI.
Factors predisposing for OH seem to be related to those for
essential hypertension, CVD (history of CE and stroke, smoking)
and metabolic disorders (diabetes, low BMI). Thus, OH may be a
part of a continuum, which comprises well-known interrelated
haemodynamic (hypertension), CVD, autonomic and metabolic
(diabetes) disorders, still representing an independent risk factor
for mortality and CE. Our study does not allow any conclusion
as to whether OH is a causative risk factor or whether it is a sec-
ondary sign of subclinical disease. However, the fact that the OH
relationship with mortality was strengthened in the younger
segment of the population, in concordance with what was
reported for the ﬁrst time in the ARIC cohort,
15–17 indicates
that OH may be causatively related to increased risk of mortality.
On the other hand, the relationship between OH and CE seemed
to be similar in those aged  42 years, whereas in the youngest
segment it was non-signiﬁcant, which partly could be explained
by less power in this group. The most deﬁnitive way to test
whether OH has a causative relationship with increased mortality
and CE risk, i.e. a randomized controlled interventional trial, is dif-
ﬁcult to design to date as there are few, if any, pharmacological
agents that conclusively have shown to improve an impaired ortho-
static response. However, the results of our study and those of the
ARIC study emphasize the need for development of novel pharma-
cological and non-pharmacological interventions for symptomatic
and non-symptomatic OH.
Apart from the dichotomous variable of OH, we analysed OBPR
as a continuous variable. Distribution of systolic and diastolic
OBPR was normal and median values were near 0 mmHg, as
expected. In crude Cox regression model, all endpoints were pre-
dicted by both variables. However, after adjustment only diastolic
OBPR independently predicted higher CE incidence. As myocardial
(especially subendocardial) perfusion occurs mainly during dia-
stole,
35 we can hypothesize that diurnal OH-related diastolic BP
ﬂuctuations inﬂuence coronary circulation to a higher degree
than postural systolic BP changes. In fact, a connection between
diastolic OH and CE was found in one study investigating home-
dwelling elderly.
13 Although symptomatic OH is usually character-
ized by falls in both systolic and diastolic BP, there was surprisingly
little overlap (8.3%) between subjects with systolic OH and dia-
stolic OH among our, presumably mainly asymptomatic, OH sub-
jects, which further supports the fact that systolic and diastolic OH
may represent different pathophysiological entities.
Our results conﬁrm that impaired orthostatic haemodynamic
response is associated with increased all-cause mortality and
increased CE incidence, whereas a relationship to stroke remains
uncertain. The latter can be partially explained by almost two
times lower stroke incidence in comparison with CE incidence.
The lower stroke incidence was, however, expected as it increases
essentially ﬁrst after the age of 65 years (1.83/1000 person-years in
those aged 55–64 vs. 5.46/1000 person-years in those aged 65–
74
36), which can be confronted with median age of 45.7 years
and mean follow-up time of 22.7 years in MPP. Although the
associations between OH and all tested endpoints were
attenuated after adjustment for traditional risk factors, a signiﬁcant
effect of baseline OH on overall mortality and CE incidence
persisted. It can be further discussed which of the results—those
from the ARIC study (relatively higher HRs) or those from the
MPP cohort—better reﬂect reality but the main conclusion
remains the same: OH confers not only higher risk for debilitating
symptoms but also for earlier death and CE. A part of the expla-
nation why the ARIC cohort demonstrated higher risks could be
demographic and epidemiological differences between two
cohorts: in the ARIC study, median age was higher (54 years),
follow-up time shorter (13 years), there were more women
(55%) and more participants with history of CVD (7%), cancer
(6%), and diabetes (12%). It is worth noting, however, that those
individuals who fulﬁlled more restrictive (i.e. higher cut-off limits)
OH criteria demonstrated similar adjusted mortality and CE risk
as OH positive individuals in the ARIC cohort. We can suppose
that methodology of BP measurements in MPP was not sufﬁciently
accurate at the time of recruitment to eliminate borderline cases.
Consequently, inclusion of false OH positive individuals in statisti-
cal analysis might have attenuated the results.
In conclusion, OH can be easily detected and its prevalence in
the middle-aged segment of the general population is close to
6%. The impaired orthostatic homeostasis is associated with age,
female gender, low BMI, hypertension, antihypertensive treatment,
higher heart rate, diabetes, and current smoking. Presence of OH
signals increased risk of mortality and CE, independently of tra-
ditional risk factors, with mortality risk particularly accentuated
in persons younger than 42 years. In addition, more pronounced
orthostatic BP drop predicts higher mortality and higher incidence
of CEs. Increased mortality in OH is related to both systolic and
diastolic impairment, whereas incidence of CEs shows stronger
association with diastolic BP fall. Further studies on pathological
mechanisms underlying OH and potential therapeutic approaches
are needed.
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